Personalis news and events
Join us as we present at upcoming conferences:
Solutions for Personalized Cancer Vaccines
Neoantigens for Personalized Cancer Vaccines: Comprehensive identification and effective selection.
Overcoming the challenges of Immuno-Oncology Biomarker Discovery: From Sample to Analytics
Personalis, Inc. receives approval from the NY State Department of Health for use of its ACE InnumoID™ platform in the cancer immunotherapeutic clinical trials.
A universal biomarker platform for immuno-oncology
Generates NeoantigenID analytics
ACE ImmunoID Platform for Tumor Immunogenomics
When one biomarker doesn’t tell the whole story
High-quality, comprehensive genomic data and analytics
Comparing and contrasting CTLA-4 and PD-L1/PD-1: A tale of two immune checkpoint inhibitors
Presentation at Rational Combinations 360°